相关实验视频
Updated: Jan 13, 2026
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
1.5K
关于CKD中足够的循环维生素D水平的当前争议
Adriana S Dusso1, Daniela J Porta1, Carlos Bernal-Mizrachi1,2
1Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, USA.
International journal of molecular sciences
|January 10, 2026
概括
在慢性病中治疗二次性甲状腺功能障碍已经将重点转移到维生素D内分泌系统,FGF23-Klotho轴和营养维生素D状态. 这些进展揭示了超出PTH控制的复杂病理生理学,需要细微的治疗策略.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 矿物质的新陈代谢.
背景情况:
- 在慢性病 (CKD) 中的二次性甲状腺功能障碍症 (SHPT) 管理在过去50年里有了显著的进化.
- 对维生素D内分泌系统在CKD进展中的作用的理解,已经被关键的发现重塑.
- 三个关键的范式转变改变了CCD中SHPT的方法.
研究的目的:
- 综合了病理生理学的见解和临床证据,这些证据是CKD中SHPT管理的重大转变的基础.
- 审查从酸替代剂到选择性维生素D受体激活剂 (VDRA) 的演变.
- 讨论营养维生素D缺乏和FGF23-Klotho轴对CKD病理生理学和治疗的影响.
主要方法:
- 对SHPT和CKD的关键病理生理学见解的审查.
- 与维生素D治疗和FGF23-Klotho轴有关的临床证据的综合.
- 分析当前治疗策略所带来的治疗困境.
主要成果:
- 选择性维生素D受体激活剂 (VDRAs) 提供了超越矿物代谢的生存益处.
- 营养维生素D缺乏在CKD中很普遍,造成死亡风险,但最佳管理是有争议的.
- FGF23-Klotho轴提出了一个治疗困境:VDRAs增加FGF23,而仿药并没有改善Klotho.
结论:
- 在CKD中SHPT的管理是复杂的,涉及到超出PTH控制的复杂相互作用.
- 需要细微的治疗策略来平衡FGF23负担和Klotho保存.
- 克服监测FGF23-Klotho轴的诊断局限性对于个性化治疗和改善CKD结果至关重要.
相关概念视频
01:28Chronic Kidney Disease III: Interprofessional Care
333
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
333
01:24Chronic Kidney Disease II: Clinical Manifestations
543
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
543
01:25Chronic Kidney Disease I: Introduction
556
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
556
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
205
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
205
01:18Chronic Kidney Disease IV: Nursing Management
312
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
312
01:11Renal Failure: Dose Adjustments
429
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
429